Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PE 0116

Next Previous
Search
Drug Profile

PE 0116

Alternative Names: Cross-linking dependent 4-1BB agonist antibody - Jiangsu HyaMab Pharmathetical; HE-0116; PE-0116; Recombinant anti-4-1BB human monoclonal antibody injection - Jiangsu HyaMab Pharmathetical

Latest Information Update: 28 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu HyaMab Pharmathetical
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 28 Apr 2024 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV, Injection)
  • 21 Sep 2023 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater, Combination therapy) in China (Parenteral) (NCT05801237)
  • 31 Aug 2023 Shanghai YingLi Pharmaceutical and Shanghai HyaMab Biotech plans phase-Ib/II trial for Solid tumours (Combination-therapy, Late-stage disease, Metastatic disease, Unresectable/Inoperable, Recurrent) in August 2023 (IV,injection) (NCT06026501),

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top